NCT01871415View on ClinicalTrials.gov

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

aleglitazar

150 mcg orally daily

DRUG

metformin

pre-existing background regimen and dose

DRUG

placebo

matching aleglitazar placebo orally daily

Trial Locations (7)

110004

Shenyang

200003

Shanghai

215004

Suzhou

442000

Shiyan

463-712

Gyeonggi-do

405-760

Incheon

150-950

Seoul

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01871415 - A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy | Biotech Hunter | Biotech Hunter